Results 71 to 80 of about 735,922 (292)

Physiological and Pharmacokinetic Alterations and Drug-Nutrient Interactions During Pregnancy

open access: yesİstanbul Medical Journal, 2017
During pregnancy, many physiological and metabolic alterations occur to support the requirements of the developing fetus. Alterations associated with the respiratory, cardiovascular, hematological, urinary, and gastrointestinal systems (GIS) may result ...
Gözde Ede, Reyhan Nergiz Ünal
doaj   +1 more source

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. [PDF]

open access: yes, 2016
BackgroundExcess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels.
Girardet, Jean-Luc   +12 more
core   +2 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Glucosamine HCl-based solid dispersions to enhance the biopharmaceutical properties of acyclovir [PDF]

open access: yes, 2019
The objective of the work presented here was to assess the feasibility of using glucosamine HCl as a solid-dispersion (SD) carrier to enhance the biopharmaceutical properties of a BCS class III/IV drug, acyclovir (ACV). The solid-dispersions of acyclovir
Bhagat, Snehal B.   +6 more
core   +1 more source

Alcohol-Induced Histone Acetylation Reveals a Gene Network Involved in Alcohol Tolerance [PDF]

open access: yes, 2013
Alfredo Ghezzi, Harish R. Krishnan, Linda Lew, Francisco J. Prado III, Darryl S. Ong, Nigel S. Atkinson, Section of Neurobiology and Waggoner Center for Alcohol and Addiction Research, The University of Texas at Austin, Austin, Texas, United States of ...
Atkinson, Nigel S.   +5 more
core   +3 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Opinions of clinicians towards use of computer applications for detecting drug-food interactions

open access: yesپیاورد سلامت, 2011
Background and Aim: Adverse events in hospitals are found to be a major problem of all health systems in the world. In fact, drug interaction side effects are now the fourth leading cause of death in the U.S.
AS Gharamaleki   +4 more
doaj  

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

open access: yesMolecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix   +13 more
wiley   +1 more source

FOOD/DRUG AND DRUG/NUTRIENT INTERACTIONS: What You Should Know About Your Medications

open access: yesEDIS, 2009
Revised! FCS-8092, a 10-page fact sheet by Linda Bobroff, Ashley Lentz, and R. Elaine Turner, describes common food/drug and drug/nutrient, and how consumers can see the potential for interactions and learn to avoid them. Includes references.
Linda B. Bobroff   +2 more
doaj   +5 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy